Back to Search Start Over

Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial

Authors :
Mathilde C.M. Kouwenhoven
Karima Mokhtari
René-Olivier Mirimanoff
Marie-France Hamou
Christian Hartmann
Danielle Martinet
Pieter Wesseling
Roger Stupp
A. von Deimling
M. J. van den Bent
Michael Weller
N Besuchet Schmutz
Wanyu L. Lambiv
Robert-Charles Janzer
Thierry Gorlia
Annie-Claire Diserens
Monika E. Hegi
Pierre Bady
Warren P. Mason
Pathology
CCA - Disease profiling
University of Zurich
Hegi, M E
Neurology
Radiation Oncology Groups
National Cancer Institute of Canada Clinical Trials Group
European Organisation for, Research
Treatment of Cancer Brain, Tumour
Source :
Acta Neuropathologica, 123(6), 841-852. Springer Verlag, Acta Neuropathologica, 123, 841-52, Acta Neuropathologica, 123(6), 841-852. Springer-Verlag, Hegi, M E, Janzer, R C, Lambiv, W L, Gorlia, T, Kouwenhoven, M C, Hartmann, C, von Deimling, A, Martinet, D, Besuchet Schmutz, N, Diserens, A C, Hamou, M F, Bady, P, Weller, M, van den Bent, M J, Mason, W P, Mirimanoff, R O, Stupp, R, Mokhtari, K & Wesseling, P 2012, ' Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial ', Acta Neuropathologica, vol. 123, no. 6, pp. 841-852 . https://doi.org/10.1007/s00401-011-0938-4, Acta Neuropathologica, 123, 6, pp. 841-52, Acta neuropathologica, Acta Neuropathologica, vol. 123, no. 6, pp. 841-852
Publication Year :
2012

Abstract

Item does not contain fulltext Glioblastoma (GBM) is a morphologically heterogeneous tumor type with a median survival of only 15 months in clinical trial populations. However, survival varies greatly among patients. As part of a central pathology review, we addressed the question if patients with GBM displaying distinct morphologic features respond differently to combined chemo-radiotherapy with temozolomide. Morphologic features were systematically recorded for 360 cases with particular focus on the presence of an oligodendroglioma-like component and respective correlations with outcome and relevant molecular markers. GBM with an oligodendroglioma-like component (GBM-O) represented 15% of all confirmed GBM (52/339) and was not associated with a more favorable outcome. GBM-O encompassed a pathogenetically heterogeneous group, significantly enriched for IDH1 mutations (19 vs. 3%, p = 0.003) and EGFR amplifications (71 vs. 48%, p = 0.04) compared with other GBM, while co-deletion of 1p/19q was found in only one case and the MGMT methylation frequency was alike (47 vs. 46%). Expression profiles classified most of the GBM-O into two subtypes, 36% (5/14 evaluable) as proneural and 43% as classical GBM. The detection of pseudo-palisading necrosis (PPN) was associated with benefit from chemotherapy (p = 0.0002), while no such effect was present in the absence of PPN (p = 0.86). In the adjusted interaction model including clinical prognostic factors and MGMT status, PPN was borderline nonsignificant (p = 0.063). Taken together, recognition of an oligodendroglioma-like component in an otherwise classic GBM identifies a pathogenetically mixed group without prognostic significance. However, the presence of PPN may indicate biological features of clinical relevance for further improvement of therapy. 01 juni 2012

Details

ISSN :
00016322
Volume :
123
Database :
OpenAIRE
Journal :
Acta Neuropathologica
Accession number :
edsair.doi.dedup.....e1a5a1d3c56b8ef520162e875697e9dd
Full Text :
https://doi.org/10.1007/s00401-011-0938-4